PF-4708671 Licensed and Manufactured by Pfizer

PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with Ki/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. First S6K1-specific inhibitor to be reported.

Price Stock Quantity  
USD 191 In stock
USD 147 In stock
USD 270 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

PF-4708671 Chemical Structure

PF-4708671 Chemical Structure
Molecular Weight: 390.41

Validation & Quality Control

Customer Product Validation(2)

Quality Control & MSDS

Related Compound Libraries

PF-4708671 is available in the following compound libraries:

Product Information

  • Compare S6 Kinase Inhibitors
    Compare S6 Kinase Products
  • Research Area

Product Description

Biological Activity

Description PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with Ki/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. First S6K1-specific inhibitor to be reported.
Targets p70 S6K1 [1]
(Cell-free assay)
IC50 160 nM
In vitro PF-4708671 is a piperazinyl-pyrimidine analogue and the first S6K1-specific inhibitor. PF-4708671 does not significantly inhibit the activity of the closely related S6K2 isoform or a number of other AGC kinases (Akt1, Akt2, PKA, PKCα, PKCϵ, PRK2, ROCK2, RSK1, RSK2 or SGK1) . PF-4708671 prevents the S6K1-mediated phosphorylation of S6 protein in response to IGF-1 (insulin-like growth factor 1), while having no effect upon the PMA-induced phosphorylation of substrates of the highly related RSK (p90 ribosomal S6 kinase) and MSK (mitogen- and stress-activated kinase) kinases. PF-4708671 is also found to induce phosphorylation of the T-loop and hydrophobic motif of S6K1, an effect that is dependent upon mTORC1 (mTOR complex 1). PF-4708671 does not affect activity of mTORC1. [1]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
BHT-101MnjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYnJR|UxRTBwOEKwNlQh|ryPMo[0V2FPT0WU
UACC-893NWrMcm92T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1:ze2lEPTB;NT6xPVg5PiEQvF2=M4DYNXNCVkeHUh?=
A427M1rnbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH31NlZKSzVyPUWuO|I2PjdizszNMV3TRW5ITVJ?
OCUB-MNHu5dJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEKyRpFKSzVyPU[uOlYyODJizszNM2ryU3NCVkeHUh?=
SW684NEL2fIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlXwTWM2OD15LkWyNlY5KM7:TR?=MknCV2FPT0WU
SK-LMS-1NXXhOllDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYnJR|UxRTlwMEGzNFIh|ryPM1XuSnNCVkeHUh?=
CP50-MEL-BMnvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUXlZlRWUUN3ME25MlMxPDF7IN88US=>NGmyWXFUSU6JRWK=
NCI-H1651MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mny4TWM2OD1zMD6wNlc3KM7:TR?=NHvtcm5USU6JRWK=
ABC-1MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlXjTWM2OD1zMD6xNFM4KM7:TR?=MX7TRW5ITVJ?
OE19MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEKzT29KSzVyPUGwMlE4OzNizszNMnvPV2FPT0WU
DSH1MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2rMXWlEPTB;MUCuPFg4QSEQvF2=MlPLV2FPT0WU
SW13MoPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXfJR|UxRTFzLkmzNVkh|ryPNIDvc5pUSU6JRWK=
MDA-MB-453NXTheoU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVnJR|UxRTF{LkG2NFMh|ryPNVnnZWhZW0GQR1XS
647-VNFTGdYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX3JR|UxRTF{LkO1PFIh|ryPMmHyV2FPT0WU
NCI-H2342NIjiTpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3ewSGlEPTB;MUKuN|k6PSEQvF2=Ml;MV2FPT0WU
LB2241-RCCM1\Jdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn\RTWM2OD1zMj61O|c6KM7:TR?=MYfTRW5ITVJ?
UACC-257NF\0R5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mom0TWM2OD1zMz60OFU{KM7:TR?=MXfTRW5ITVJ?
NCI-H661NEmyc|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn;CTWM2OD1zMz62OFQ6KM7:TR?=NGrmdZRUSU6JRWK=
FADUNYfSXFFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkO0TWM2OD1zMz62PVkzKM7:TR?=M3XyUnNCVkeHUh?=
A2780M3rRd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlrHTWM2OD1zMz64NFQyKM7:TR?=NV\tb3VCW0GQR1XS
NCI-H1793MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn3iTWM2OD1zND60NFg2KM7:TR?=M3nq[3NCVkeHUh?=
TE-8MmT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{\mdmlEPTB;MUWuN|Q3PSEQvF2=M336U3NCVkeHUh?=
HGC-27M4jGR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn\FTWM2OD1zNj6xOlQ1KM7:TR?=NYGxUYhOW0GQR1XS
MMAC-SFMlHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2S5OmlEPTB;MUeuN|czPyEQvF2=MYHTRW5ITVJ?
Calu-6Mm\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYnxZZgyUUN3ME2xPE4yPTF|IN88US=>NVvFO49XW0GQR1XS
HUTU-80NXXNVFhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHfPXYhKSzVyPUG4MlM6PTlizszNM1fPSHNCVkeHUh?=
SASNHXabFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoXQTWM2OD1zOD62OFU2KM7:TR?=MV;TRW5ITVJ?
IST-MES1NU[3ToxiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NID4[4hKSzVyPUG4MlY2ODhizszNMYDTRW5ITVJ?
C3ANXvTR5BkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnrRTWM2OD1zOD63PVE6KM7:TR?=Mo\nV2FPT0WU
ES3M3LiOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUjM[olHUUN3ME2xPE45OzZ2IN88US=>MUjTRW5ITVJ?
HSC-2NFnkeW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHf3S|VKSzVyPUG5MlY2PDFizszNMVTTRW5ITVJ?
T47DM3L5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1zzNmlEPTB;MkCuNVQ5PSEQvF2=NVTYTG96W0GQR1XS
EW-7MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHGyPW1KSzVyPUKwMlg2QDhizszNNGq3NWRUSU6JRWK=
LN-405MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHTqe|ZKSzVyPUKwMlg6PjVizszNNV;NU4xiW0GQR1XS
U031NXv0NFlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFW0T4VKSzVyPUKxMlQ5ODJizszNMoXKV2FPT0WU
A549MoDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUDJR|UxRTJzLki0PVEh|ryPMlfvV2FPT0WU
RMG-IMnH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWTJR|UxRTJ{LkK2Olgh|ryPMoXUV2FPT0WU
BT-474MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGi1T4JKSzVyPUKyMlY2PTFizszNM4HESHNCVkeHUh?=
NB69NITnNFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYLWbmQ4UUN3ME2yN{4yPTJizszNMVTTRW5ITVJ?
NB7MlOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NU[0[2RpUUN3ME2yOE4yQDhizszNMlL1V2FPT0WU
HCC1569NIHrRlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF62U2hKSzVyPUK0MlYyOjVizszNMn\SV2FPT0WU
MEL-JUSONVfRN5NkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn\sTWM2OD1{ND62PVA5KM7:TR?=NHvXUWxUSU6JRWK=
MDA-MB-175-VIIMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NY\1b2REUUN3ME2yOU4zPTF5IN88US=>MX7TRW5ITVJ?
HCC1419NGnqXGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFX5dI9KSzVyPUK1MlYxODNizszNMnjTV2FPT0WU
Ca9-22NUHNS4JTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWDsT3RvUUN3ME2yOU43PDN{IN88US=>M4LLW3NCVkeHUh?=
KGNMV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3;FWWlEPTB;MkWuO|U1PyEQvF2=NVzqPWIxW0GQR1XS
LB373-MEL-DNWHBfJNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3vaN2lEPTB;Mk[uNVk{QCEQvF2=NGK2TphUSU6JRWK=
NCI-H1755M3rrcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4KwRmlEPTB;Mk[uPFg1OSEQvF2=MVXTRW5ITVJ?
D-423MGMmLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlrCTWM2OD1{Nz6wO|E2KM7:TR?=MV3TRW5ITVJ?
DK-MGMonmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoPMTWM2OD1{OD63PFQ3KM7:TR?=MWLTRW5ITVJ?
NCI-H1623MoSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MY\JR|UxRTJ6LkizOFIh|ryPMo\tV2FPT0WU
KU-19-19MnXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYC1UmlYUUN3ME2yPE46QTVizszNMV7TRW5ITVJ?
C-33-ANVPjVJl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGXvO5JKSzVyPUK5MlIyQThizszNNYG2V4NOW0GQR1XS
SCC-4Mn21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmG1TWM2OD1|MD6zN|U1KM7:TR?=MXTTRW5ITVJ?
MG-63M4\p[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M12wUWlEPTB;M{CuOVk6PCEQvF2=MmCwV2FPT0WU
LNCaP-Clone-FGCM2W4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHPlfG5KSzVyPUOxMlQ6OjFizszNMorWV2FPT0WU
CAPAN-1MkXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIL3S3BKSzVyPUOxMlUzQDZizszNNITHRXJUSU6JRWK=
GI-ME-NNGDXdXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4XZTGlEPTB;M{GuOVM2OyEQvF2=NX;XdHIzW0GQR1XS
RERF-LC-MSNFPRUVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUPJR|UxRTN{Lk[3OFch|ryPMnmxV2FPT0WU
KLEMVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWi2SlBHUUN3ME2zN{41OzN2IN88US=>NGnOUGRUSU6JRWK=
KNS-81-FDM3vjVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3fuO2lEPTB;M{OuOVAxQCEQvF2=MknpV2FPT0WU
DOKMVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnWyTWM2OD1|ND62OlEzKM7:TR?=Mm\wV2FPT0WU
ACHNNIWxbmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIewRpRKSzVyPUO1MlE2QDhizszNMn7iV2FPT0WU
KYSE-520NGrCd3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYfJR|UxRTN3LkKzOlEh|ryPNFzQXIlUSU6JRWK=
SBC-5NGjpR2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NG\YVItKSzVyPUO1MlUyOTZizszNNIDkOZBUSU6JRWK=
NCI-H28NH3QSXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGPnN4dKSzVyPUO1MlY3QTVizszNM1\sO3NCVkeHUh?=
ES7MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4LTcmlEPTB;M{[uNlI1QSEQvF2=NX\4WmhjW0GQR1XS
A172M1njemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkD6TWM2OD1|Nj60NVg4KM7:TR?=MnvWV2FPT0WU
UM-UC-3MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVHwclM2UUN3ME2zO{45PzR4IN88US=>NWLXSZZbW0GQR1XS
LXF-289MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M33VVmlEPTB;M{iuNFA1PyEQvF2=Mn;rV2FPT0WU
KP-4M1[0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1TWeGlEPTB;M{iuOFc{QSEQvF2=NVT5To9EW0GQR1XS
TE-1NUDVVnh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXLJR|UxRTN7Lk[1PFkh|ryPNITwRmZUSU6JRWK=
G-402NI\XcZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEi5fGdKSzVyPUSwMlA3OSEQvF2=NVvlWFR7W0GQR1XS
786-0NV3F[XlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3zkRWlEPTB;NECuPVA6PiEQvF2=Ml3kV2FPT0WU
K5MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmfnTWM2OD12MT6zOlg3KM7:TR?=M3LwZ3NCVkeHUh?=
SK-N-DZMoT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVTNboY{UUN3ME20NU4{QDJ|IN88US=>M3;JXHNCVkeHUh?=
OVCAR-4MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MULJR|UxRTRzLke1Olgh|ryPMoqyV2FPT0WU
T84NVXPcJplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHfaOVNKSzVyPUSyMlEzPjNizszNNF;SdWVUSU6JRWK=
GCIYM{\RcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYrJR|UxRTR|LkC4NFMh|ryPMlL5V2FPT0WU
BB49-HNCMkW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIrrRWtKSzVyPUSzMlM{PDhizszNMl;mV2FPT0WU
SNU-C2BMY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFXi[WtKSzVyPUSzMlY1OzZizszNMY\TRW5ITVJ?
TE-6MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml;vTWM2OD12Mz64PFk1KM7:TR?=M{P2XXNCVkeHUh?=
23132-87MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGnoNHZKSzVyPUS0MlI6PzhizszNMW\TRW5ITVJ?
DMS-53MljDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUPoTFBuUUN3ME20OE4{Ozh2IN88US=>NVu3[|J3W0GQR1XS
ONS-76NV3LSYRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3\tZmlEPTB;NESuO|Y3OSEQvF2=NUPhbldvW0GQR1XS
DMS-273MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEizeGJKSzVyPUS0Mlk1OyEQvF2=M1rtOnNCVkeHUh?=
COLO-824NIr4[JFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYXWZZdYUUN3ME20OU45Pzd3IN88US=>NYXIXGZXW0GQR1XS
DMS-114M3\zOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUjJR|UxRTR3Lki5Nlch|ryPM3HGNHNCVkeHUh?=
YKG-1MoLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmPQTWM2OD12Nj6wN|U2KM7:TR?=NWrIWY0yW0GQR1XS
RH-18MoHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoexTWM2OD12Nj6zO|M{KM7:TR?=MYXTRW5ITVJ?
NCI-H1355NGGwdI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHvrSnpKSzVyPUS2MlYyQCEQvF2=NIHQU3FUSU6JRWK=
NCI-H2170M4XxZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGPJZoxKSzVyPUS3Mlc2QDRizszNMWLTRW5ITVJ?
OC-314NFKySFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NInue3lKSzVyPUS3Mlg1PzhizszNNXzp[3BKW0GQR1XS
NCI-H2030NVmwUm11T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NILwUVdKSzVyPUS3Mlg6ODZizszNMlO4V2FPT0WU
22RV1MkXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MW\JR|UxRTR5LkmwNVUh|ryPMoO4V2FPT0WU
G-401NUDIWY5qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NILMWlRKSzVyPUS4MlQ1OTVizszNNGrHRm1USU6JRWK=
YAPCM{\vNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUfJOpBYUUN3ME20PU45ODd|IN88US=>M2XFZnNCVkeHUh?=
SW1573MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmG1TWM2OD13MD6yOFM2KM7:TR?=NWnDTlVsW0GQR1XS
COLO-792NUCzSGxuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmjNTWM2OD13MD62NlM4KM7:TR?=MlLoV2FPT0WU
KNS-62NIjxUJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3vFRWlEPTB;NUCuO|UxQCEQvF2=NWjoVFRsW0GQR1XS
NB5MojkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYfJR|UxRTVzLkS1NFkh|ryPNV35NI9mW0GQR1XS
CP66-MELMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWjJR|UxRTVzLk[0NFgh|ryPNITaUXJUSU6JRWK=
CaR-1M1rwUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn7qTWM2OD13Mj6wOlA3KM7:TR?=MlTDV2FPT0WU
CAL-54MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NImwSotKSzVyPUWyMlEyODJizszNMkLHV2FPT0WU
8305CMXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2C3OWlEPTB;NUKuN|E2KM7:TR?=MmnnV2FPT0WU
Calu-3M1zKeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTV{LkO3N|Mh|ryPNHzsbHJUSU6JRWK=
AU565MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGD6UHhKSzVyPUWyMlU2ODlizszNMUXTRW5ITVJ?
CW-2MkPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUXzVndoUUN3ME21Nk45PjV2IN88US=>MoPkV2FPT0WU
BENMULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXfJR|UxRTV|Lke4OlIh|ryPMlLCV2FPT0WU
NCI-H1975NH61e3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWrJR|UxRTV|Lki5OlYh|ryPMV7TRW5ITVJ?
HCT-116MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NI\iRnJKSzVyPUW0MlA{OjdizszNMmXSV2FPT0WU
SH-4NVHHUYdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEjIdWRKSzVyPUW0MlE{QCEQvF2=MW\TRW5ITVJ?
NCI-H1693MljSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVzJR|UxRTV2LkKxNFMh|ryPM4fNeHNCVkeHUh?=
BPH-1NFn1TIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXvJR|UxRTV3LkK4PVIh|ryPNXTJU|dlW0GQR1XS
CAMA-1MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4nYO2lEPTB;NUWuPFEyPiEQvF2=NILkXlBUSU6JRWK=
A388MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYPzWHUzUUN3ME21Ok4xQTh3IN88US=>MX7TRW5ITVJ?
C2BBe1NXrZSmNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVrhWnNtUUN3ME21Ok4zPjN2IN88US=>NYDSVJQ4W0GQR1XS
GAMGNFjVcZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWXJR|UxRTV4LkW5OVUh|ryPM{ixTnNCVkeHUh?=
MKN28M4fZVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2TRSGlEPTB;NU[uPFAyOyEQvF2=MlHqV2FPT0WU
VA-ES-BJNH6yWFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3jBeGlEPTB;NU[uPFc1PSEQvF2=MV3TRW5ITVJ?
HuCCT1MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGW2OFVKSzVyPUW3MlA1QTJizszNNF7tc4lUSU6JRWK=
BFTC-905M1njT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MY\JR|UxRTV5LkK4PVgh|ryPMUTTRW5ITVJ?
LS-123NHnje3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYDqZZViUUN3ME21O{42PjZ6IN88US=>Mor0V2FPT0WU
LB996-RCCNYrvUGltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn;RTWM2OD13OD6wNlg4KM7:TR?=M122dHNCVkeHUh?=
NCI-H1048NHrKcXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnnnTWM2OD13OD6yNVg5KM7:TR?=Ml33V2FPT0WU
COR-L105M2\QR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmLXTWM2OD13OD63N|M4KM7:TR?=MnzlV2FPT0WU
OVCAR-8M1ryW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mnq1TWM2OD13OT6xO|E3KM7:TR?=M4D4U3NCVkeHUh?=
SK-N-FIMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWPYdmVUUUN3ME21PU4{OjB5IN88US=>NUjwVXp2W0GQR1XS
MES-SANF3JU2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2W1SWlEPTB;NUmuOFUxQSEQvF2=MUDTRW5ITVJ?
SCC-9NIX0[41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3\nVGlEPTB;NUmuOFc2OyEQvF2=NUDCfG1jW0GQR1XS
EFO-27NWntOWs{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkDrTWM2OD13OT65OFMh|ryPNVv5SXhqW0GQR1XS
GT3TKBNIT2eW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWLJR|UxRTZyLk[wOFgh|ryPM{fIXXNCVkeHUh?=
HCC38Ml[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXTjeFJiUUN3ME22NU41Ozd7IN88US=>MkDKV2FPT0WU
MLMAMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MY\JR|UxRTZzLk[xOlMh|ryPNFG1XnRUSU6JRWK=
D-566MGNI\Ve|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYrJR|UxRTZ|LkWyNlQh|ryPMn7wV2FPT0WU
SF295MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWLJV4VsUUN3ME22N{43PjV3IN88US=>MV7TRW5ITVJ?
ES4NGXQVIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mny3TWM2OD14ND60O|E6KM7:TR?=NX7MXW5OW0GQR1XS
CAKI-1M3K3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV;JR|UxRTZ2LkW3NlEh|ryPNVftZmtqW0GQR1XS
OAW-28M3j1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHv6dY9KSzVyPU[0Mlk3PDdizszNNUDmVVVOW0GQR1XS
NCI-H460NXHMW5pYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVfJR|UxRTZ3LkC4PVch|ryPMorZV2FPT0WU
JARNHHQWZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MknMTWM2OD14NT61OVE3KM7:TR?=NXiyPYtYW0GQR1XS
SNU-449M1uyc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUTJR|UxRTZ3Lke2NVYh|ryPNUjqelM{W0GQR1XS
D-392MGMXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXjqbmNwUUN3ME22OU46PDN2IN88US=>M4jZSXNCVkeHUh?=
EW-22MoHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUDabnZYUUN3ME22Ok4{QTVizszNMYfTRW5ITVJ?
GCTNH;UOGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXjJR|UxRTZ5LkC0OFMh|ryPNGTu[mhUSU6JRWK=
NOS-1MofvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH;0VFRKSzVyPU[3MlY5PjdizszNMkPTV2FPT0WU
RH-1M3TkXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M33ZeWlEPTB;NkiuOVU2QSEQvF2=NEPmPZdUSU6JRWK=
HuH-7M{TVTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHvNeHJKSzVyPU[5MlExODJizszNMWXTRW5ITVJ?
NUGC-3NIPKW49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGLJ[4JKSzVyPUewMlk3PDRizszNMoXxV2FPT0WU
IST-SL1MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWO3d2U2UUN3ME23NU4zOzJ2IN88US=>MUHTRW5ITVJ?
SHP-77NEfsUHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MojJTWM2OD15Mj6xNVkh|ryPNYPq[4RnW0GQR1XS
SW1116M1:2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4f4R2lEPTB;N{KuNVQxPyEQvF2=MXLTRW5ITVJ?
LK-2MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlfXTWM2OD15Mj64OlEzKM7:TR?=M3PD[nNCVkeHUh?=
U-2-OSM{LGTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NE[5[lZKSzVyPUezMlE5OjhizszNNWDnVmdrW0GQR1XS
KYSE-150Mnm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVnJR|UxRTd|Lk[xNVgh|ryPNYr5[|JCW0GQR1XS
U251NY\DfXRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH\lWnpKSzVyPUezMlgyPjhizszNMl;KV2FPT0WU
HT-1080MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHLBOnJKSzVyPUe0MlI2PzRizszNMnHzV2FPT0WU
NCI-H1437MlXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVvJR|UxRTd2Lk[zNlYh|ryPNVLnU3BRW0GQR1XS
HPAF-IIM{\UNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFjmUIpKSzVyPUe0MlY1OTVizszNNX3lNnlQW0GQR1XS
BeckerMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX7JR|UxRTd3LkGxNFUh|ryPNV7GXGFEW0GQR1XS
PANC-10-05MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mne4TWM2OD15NT6yPFY2KM7:TR?=Mk[xV2FPT0WU
TYK-nuM{W2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX34VIhOUUN3ME23OU4{OTB{IN88US=>MkT4V2FPT0WU
SKG-IIIaM4LxRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH3T[FVKSzVyPUe1MlM{PDFizszNNYTQUFV7W0GQR1XS
NCI-H1993MmP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXv4VHY2UUN3ME23OU44Ozl5IN88US=>NGHOTIFUSU6JRWK=
S-117M4HYNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXqzT3c2UUN3ME23OU44PTVizszNMW\TRW5ITVJ?
HuO9MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUXJR|UxRTd4LkCwOFgh|ryPM3fMUXNCVkeHUh?=
CAL-51Ml3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnrDTWM2OD15Nj6xNFA3KM7:TR?=NWjFWWoxW0GQR1XS
BT-20M3f3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVjUbJVSUUN3ME23Ok4zOTZ6IN88US=>NEHlN|dUSU6JRWK=
LB831-BLCNGTHclZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4jScWlEPTB;N{[uN|IyPyEQvF2=MnTWV2FPT0WU
LB1047-RCCMnzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHywSG1KSzVyPUe2Mlc3OTlizszNNGT2TpNUSU6JRWK=
ES8NFjVZlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFXD[5dKSzVyPUe4MlAxPzNizszNNV\TU3ZyW0GQR1XS
UMC-11M{XKc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYnJR|UxRTd6LkC4PFQh|ryPNHvMNGZUSU6JRWK=
NCI-H226NGXEXFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWHJR|UxRTd6LkGzNVUh|ryPM1O0TnNCVkeHUh?=
IGROV-1NGruW2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlzLTWM2OD15OD61OVUh|ryPMULTRW5ITVJ?
BHYMofvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUPJR|UxRTd7LkW5OkDPxE1?MkHIV2FPT0WU
MKN45MkPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3\sc2lEPTB;OECuN|E4PCEQvF2=M1vQNHNCVkeHUh?=
IA-LMNIXm[pJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXjyRplzUUN3ME24NE4{PTFzIN88US=>MWrTRW5ITVJ?
WM-115NYTae2ZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX\JR|UxRThzLkSxNVQh|ryPMVPTRW5ITVJ?
VMRC-RCZMUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHPmW3ZKSzVyPUixMlQ1OjVizszNNVnFeYN3W0GQR1XS
NCI-H2291MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2TLUGlEPTB;OEGuOlg1OiEQvF2=MnrTV2FPT0WU
MCF7NHjBSZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoXwTWM2OD16Mz6yPFk4KM7:TR?=MlznV2FPT0WU
639-VNF7j[3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWTJR|UxRTh2Lk[xNlkh|ryPMXnTRW5ITVJ?
RT4M2LYVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnW5TWM2OD16NT6yOFA{KM7:TR?=NY[3ZoFoW0GQR1XS
NCI-H2405NXjRTm44T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUjGbIFEUUN3ME24OU4zQTl5IN88US=>MXLTRW5ITVJ?
CAL-33M1;oU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEG3PIZKSzVyPUi1MlY{OTVizszNNELSblJUSU6JRWK=
BT-549MoDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkT0TWM2OD16NT65N|gzKM7:TR?=NW\DRolJW0GQR1XS
HT-1197MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYDQU2RlUUN3ME24PE4yODd5IN88US=>MojlV2FPT0WU
G-361NX7YOWh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYTKPG1JUUN3ME24PE4yPDd2IN88US=>NY\LcWRIW0GQR1XS
LS-411NNU\FW4dLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml\tTWM2OD16OT6zN|g5KM7:TR?=NGLmUVdUSU6JRWK=
HT-144M4H3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX7JR|UxRTh7LkW5PVIh|ryPNHe0NVdUSU6JRWK=
DJM-1M4rqWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUO1RppzUUN3ME24PU45QDR3IN88US=>NIXyelVUSU6JRWK=
CAL-12TNGTsOWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV7PRVg3UUN3ME25NE44QDl3IN88US=>MVPTRW5ITVJ?
MKN7MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVnJR|UxRTlzLkO1OVEh|ryPMlzNV2FPT0WU
HuP-T3Mkj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUnBNYRNUUN3ME25Ok4yODB2IN88US=>NFL3U3FUSU6JRWK=
SK-MG-1NHHHNoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVLJR|UxRTl4LkGzOFgh|ryPNVq1OYtPW0GQR1XS
NCI-H2347MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVL5NYlUUUN3ME25PE4yODR{IN88US=>M4T2THNCVkeHUh?=
SW872MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWLJR|UxRTFyMD60OVYh|ryPMUXTRW5ITVJ?
COLO-829NVuzU3ROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUnJR|UxRTFyMD61OVMh|ryPM2Tse3NCVkeHUh?=
MC-IXCNFvzPINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1XDTWlEPTB;MUCwMlYyPSEQvF2=M{HK[HNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo
Features

Protocol(Only for Reference)

Kinase Assay: [1]

Protein kinase activity assays For selectivity IC50 assays, purified active GST–S6K1, GST–S6K2, His–MSK1 (residues 2–802), His–RSK1 (residues 1–735) and His–RSK2 (residues 2–740) (0.5 units/mL) are assayed for 30 min at 30 °C in a 50 μL assay mixture in buffer A containing either 30 μM Crosstide (GRPRTSSFAEG, for S6K1, S6K2 and MSK1) or 30 μM Long S6 (KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK, for RSK1 and RSK2), 10 mM magnesium acetate and 100 μM [γ- 32P]ATP. Reactions are terminated and the incorporation of [γ-32P]phosphate into the peptide substrate is determined by applying the reaction mixture on to P81 phosphocellulose paper and scintillation counting after washing the papers in phosphoric acid. One unit of activity is defined as that which catalysed the incorporation of 1 nmol of [32P]phosphate into the substrate. To determine the Ki for PF-4708671, full-length recombinant S6K1 is added to a final concentration of 5 nM to Omnia assay buffer containing various concentrations of compound. The reaction is run for 60 min at 30 °C in a 50 μL assay volume. The fluorescence of the peptide is monitored at an excitation wavelength of 360 nm and an emission wavelength of 485 nm. The rate of the reaction at each compound concentration is normalized to the DMSO control rate, and this normalized rate against concentration is fitted to the Morrison tight-binding equation for a competitive inhibitor to provide the true Ki. In order to assay S6K activity in HEK-293 cell lysates, cells are lysed in Tris lysis buffer. Lysate (0.5 mg) is incubated with 5 μg of S6K antibody conjugated to Protein G–Sepharose for 1 h at 4 °C on a vibrating platform. Immunoprecipitates are washed twice with lysis buffer and twice with buffer A, and kinase activity is assayed exactly as described above using the Crosstide peptide.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Pearce LR, et al. Biochem J, 2010, 431(2), 245-255.

Chemical Information

Download PF-4708671 SDF
Molecular Weight (MW) 390.41
Formula

C19H21F3N6

CAS No. 1255517-76-0
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 30 mg/mL (76.84 mM)
Ethanol 8 mg/mL (20.49 mM)
Water <1 mg/mL (<1 mM)
In vivo 30% PEG400/0.5% Tween80/5% propylene glycol 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 1H-Benzimidazole, 2-[[4-(5-ethyl-4-pyrimidinyl)-1-piperazinyl]methyl]-6-(trifluoromethyl)-

Customer Product Validation (2)


Click to enlarge
Rating
Source Mol Cancer Ther, 2015, 14(3): 799-809. PF-4708671 purchased from Selleck
Method Apoptosis & Proliferation Assays
Cell Lines Nude mice tumor tissue
Concentrations 60 mg/kg
Incubation Time 15 d
Results The tumor tissues from OSI-906+PF-4708671–treated mice showed the most TUNEL-positive staining and the least Ki-67–positive staining.

Click to enlarge
Rating
Source PLoS One 2014 9(2), e90388. PF-4708671 purchased from Selleck
Method Western blot
Cell Lines QBC939, RBE, HCCC-9810 cells
Concentrations 10 uM
Incubation Time 48 h
Results It is notable that p70S6K inhibitor PF-4708671, which had no demonstrable effects on ATF4 and GRP78 accumulation, enhanced the decreasing of ATF4 and GRP78 in 4EGI-1-treated QBC939, RBE and HCCC-9810 cells.

Product Use Citation (5)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related S6 Kinase Products

  • LY2584702

    LY2584702 is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.

  • LY2584702 Tosylate

    LY2584702 Tosylate is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.

  • CHIR-99021 (CT99021)

    CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively.

  • BI-D1870

    BI-D1870 is an ATP-competitive inhibitor of S6 ribosome for RSK1/2/3/4 with IC50 of 31 nM/24 nM/18 nM/15 nM in cell-free assays, respectively; 10- to 100-fold selectivity for RSK than MST2, GSK-3β, MARK3, CK1 and Aurora B.

  • Rapamycin (Sirolimus)

    Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

  • MK-2206 2HCl

    MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

    Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.

  • CHIR-99021 (CT99021) HCl

    CHIR-99021 (CT99021) HCl is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM in cell-free assays; ability to distinguish between GSK-3 and its closest homologs Cdc2 and ERK2.

  • LY294002

    LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM in cell-free assays, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation.

  • 3-Methyladenine (3-MA)

    3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation.

  • Everolimus (RAD001)

    Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay.

Recently Viewed Items

Tags: buy PF-4708671 | PF-4708671 supplier | purchase PF-4708671 | PF-4708671 cost | PF-4708671 manufacturer | order PF-4708671 | PF-4708671 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us